Wu Lin

City:

Nottingham

Country:

United Kingdom

Published Applications:

Last publication date:

2026-01-08

Top Assignees for applications by Wu Lin

The entities that hold a legal rights for patent applications filed by inventor Lin Wu:

Principia Biopharma Inc. 2 Bridgewater, NJ United States
Evecxia Therapeutics, Inc. 2 Research Triangle Park, NC United States
Principia Biopharma Inc. 1 South San Francisco, CA United States
VERTEX PHARMACEUTICALS INCORPORATED 1 Cambridge, MA United States
Corcept Therapeutics Incorporated 1 Redwood City, CA United States

Recent patent applications by Lin Wu

Wu Lin from Nottingham, GB has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-01-08

US20260007653A1

Human necessities

FORMULATIONS OF GLUCOCORTICOID RECEPTOR MODULATORS

#2 | 2025-12-18

US20250381193A1

Human necessities

Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-yl]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-yl)Piperazin-1-yl]Pent-2-Enenitrile

#3 | 2024-06-27

US20240207275A1

Human necessities

Modified Release Formulations of 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl) Pyrazolo[3,4-D] Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl -4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile

#4 | 2024-04-25

US20240131020A1

Human necessities

FORMULATIONS OF GLUCOCORTICOID RECEPTOR MODULATORS

#5 | 2024-04-04

US20240108582A1

Human necessities

5-HYDROXYTRYPTOPHAN GASTRORETENTIVE DOSAGE FORMS

#6 | 2023-02-16

US20230047338A1

Human necessities

5-hydroxytryptophan gastroretentive dosage forms

#7 | 2021-04-22

US20210113567A1

Human necessities

Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

#8 | 2011-01-27

US20110021598A1

Human necessities

CONTROLLED RELEASE FORMULATIONS

InventorID:

3333223 ⎘